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Abstract
Here, we present results from two independent studies carried out using Neuromolecular Imaging (NMI) with 
miniature BRODERICK PROBE® biosensors. In the first study, we imaged neurotransmitters and neurochemicals 
in human epilepsy patients intraoperatively during early and late neurodegeneration. In the second study, we 
imaged neurotransmitters and neurochemicals in an experimental murine model using animals with and without 
neurodegeneration caused by Parkinson’s disease (PD). We compared our results derived from animals with 
lesioned group (PD) with non-lesioned group (non-PD), using the same in vivo NMI paradigm. NMI biotechnology 
enabled neurotransmitters, neuropeptides and neurochemical imaging of dopamine (DA), serotonin (5-HT), 
homovanillic acid (HVA), L-tryptophan (L-TP), dynorphin A (DYN A) and somatostatin (SRIF).  Each neurotransmitter 
and neurochemical was imaged at its respective signature i.e., its electroactive oxidation/half-wave potential. 
Results showed neuropeptide signatures of DYN A and SRIF as common biomarker molecules following late 
neurodegeneration in epilepsy patients and in PD animal models. Placing these two studies together allowed us to us 
to provide a new hypothesis about a possible biomarker link between the two neurodegenerative diseases, epilepsy 
and PD. Interestingly, this biomarker link, to our knowledge has not been observed previously. These findings will 
provide new strategies for better diagnoses, detection of and protection against epilepsy and Parkinson’s disease.
Keywords: Neurodegeneration; Biomarker; Neuromolecular
Imaging; Epilepsy; Neurotransmitter; Parkinson’s Disease; Human 
hippocampus; Dopamine; Serotonin; Dynorphin; Somatostatin; 
L-tryptophan; Homovanillic acid; Neuropeptides; Brain injury;
Microelectrode
Introduction 
Progressive cell death in brain neuronal circuits occurs far too often 
from brain injuries caused by diseases such as Epilepsy, Parkinson’s 
disease and Alzheimer’s disease. Epilepsy is a neurological disorder 
characterized by repeated seizures over time [1]. In this disorder, 
the brain exists in an excitable state, increasing neuronal firing rates 
resulting in abnormally repeated signals accompanied by seizures. 
Epilepsy may result due to various causes such as stroke, dementia, 
traumatic brain injury, infections (meningitis, encephalitis, and AIDS), 
brain tumor, brain injury and congenital brain defect.
Parkinson’s disease (PD) is the second most common progressive 
neurodegenerative disease in America [2]. It is characterized by the 
formation of Lewy bodies and Lewy neurites in dopaminergic (DA) 
neurons of substantia nigra pars compacta (SNpc) of brain. Symptoms 
include progressive impaired movement as (a) uncontrollable resting 
tremors (b) bradykinesia, (c) muscle rigidity and (d) postural instability. 
Consistent loss of DA neurons results in the depletion of dopamine 
level of brainstem and striatal projections, involved in motor function 
of CNS. 
Several animal model studies have been conducted to provide 
further insight into PD and its therapies. However, more experimental 
approaches are required to elucidate the precise mechanism of action 
of PD involved with DA neurons in nigrostriatal pathways. One of the 
major obstacles in the human studies of PD is that brain materials from 
early or untreated PD patients are unavailable. In addition, there are 
minimal amounts of animal studies with few published reports to date 
about in vivo dynamic release of neurotransmitters, neurochemicals 
and/or neuropeptides in PD animals. Neuromolecular Imaging (NMI) 
is the first in vivo, real time imaging technique using BRODERICK 
PROBE® biosensor to image concentrations of different critical 
neurotransmitters involved in stroke, epilepsy and Parkinson’s disease.
Here, we present studies that are primarily focusing over the real 
time changes associated with brains following neuro-degeneration in 
human epilepsy patients (early v/s late neurodegeneration) and PD v/s 
non-PD animal models. We are the first to demonstrate appearance 
of neuropeptides as hallmark of neurodegeneration and related 
biomarkers for epilepsy and PD.
Principle of neuromolecular imaging
Figure 1 illustrates the NMI setup using BRODERICK PROBE® 
biosensor: These biosensors have been tested in controlled studies 
and details of NMI biotechnology and circuitry are already published 
[3-13]. NMI works on utilizing electron transfer kinetics by selecting 
an image of a specific neurochemical or neurotransmitter molecule 
at an electroactive oxidation/half wave potential. Specific biosensor 
properties such as hydrophobicity, hydrophilicity, side chains of amino 
acids of biosensor formulation determine current derived from electron 
transfer kinetics upon interaction with specific neurotransmitters and 
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neuropeptides. The electroactive signature for each molecule is detected 
by a detector/potentiostat in subunits of volts and amperes, depending 
upon the type of electronic circuitry chosen in the potentiostat for a 
particular study. Potentiostat is connected to an external chart recorder 
to record signals obtained in form of signature oxidation/half wave 
potential. For both circuitry i.e., linear or semi-differential/semi-
derivative, x-axis represents voltage in millivolts and y-axis represents 
current in microamperes. 
In vivo studies of brain neurotransmitters based on electrochemistry 
have been in progress [14-16] and advancements have been made in 
voltammetry and microvoltammetry using carbon fiber electrodes 
[17,18]. The basic electrochemical principles of voltammetry are listed 
below:
• To measure the current as a function of applied voltage, when an 
electroactive species undergo redox reaction at a characteristic redox 
potential.
• Formulae: O+ne-↔R, where, ne=number of electrons, 
O=oxidation, R=reduction.
• Current produced by specific redox reaction is directly 
proportional to concentration of neurotransmitter, given by the Cottrell 
equation described below:
1/2 1/2 1/2/ 3.14t o oi nFAC D t=
where:  
o=concentration of electroactive species oxidized
i=current at time, t 
n=number of electron transfers, eq/mol 
F=Faraday’s constant, 96486 C/eq 
A=electrode area, cm2
C=concentration of O, mol/cm3
D=Diffusion coefficient of O, cm2/s
Conventional voltammetry and microvoltammetry methods 
since 1970’s have validated that the flow of charge (current in 
amperes) through the surface of indicator is directly proportional to 
concentration of electroactive species. Relationship in term of charge, 
current, concentration of electroactive species, time, diffusion layer, 
size of indicator electrode, electron transfer and Faraday’s constant are 
described below in term of derived equations:
0
,
/
/
R
R t
Q nFVC
i dQ dt
i nFVdC dt
=
=
=
where:
V=volume of the diffusion layer on the electrode of measurement
n=number of transferred electrons
F=Faraday’s Constant
Co=initial concentration
Material and Methods
NMI, intra-operative clinical studies in epilepsy patients
NMI, based on electrochemical principles, has made major 
advances in the field of nanobiotechnology, science and medicine. For 
example, one of these cutting-edge advancements made by NMI and the 
BRODERICK PROBE® is in the field of human epilepsy intraoperatively 
in NYU Tisch Hospital with Institutional Review Board (IRB) approval 
(Figure 2).   
Studies in real time with NMI and BRODERICK PROBE® 
biosensors begin with electroencephalographic (EEG) monitoring 
wherein the site of cortical resection is defined with subdural grid 
epilepsy electrodes which are placed on the surface of the brain and 
epilepsy strip electrodes are placed subtemporally. 
Then, BRODERICK PROBE® biosensors, with a diameter over 
five times smaller than epilepsy depth electrodes for invasive EEG, are 
placed by direct visualization in the exposed cortical region with and 
without epileptic spike activity in regions destined for resection. 
About six to ten recordings with γ-irradiated [11.6-12.7 kilograys 
(kGys)], laminar biocompatible carbon-based BRODERICK PROBE® 
The BRODERICK  PROBE®
for human and animal studies:
Applies potential to
sensor Sensor detects
neurochemical
concentrations in
brain tissue
Neurochemical
signatures at
specific potentials
imaged by
hardware-
software
interface
Figure 1: Schematics of NMI setup. BRODERICK PROBE® is implanted to 
live brain tissue and then externally connected to the potentiostat to apply 
potential. Upon interaction with specific neurochemical, the BRODERICK 
PROBE® transfers its signature electroactive oxidation potential to hardware-
software interface for data interpretation and recording.
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Figure 2: NMI results from resected epileptogenic tissue of hippocampal 
pyramidal layer (Gray matter) in early neurodegeneration: Monoamines: 
Dopamine (DA), Serotonin (5-HT). On the x-axis: oxidation potential in term of 
applied voltage in volts (V). On the y-axis: current in picoamperes (pA). Note 
that the x-axis terminates at approximately 0.45V due to the low detection limit 
of L-tryptophan and neuropeptides in early neurodegeneration.
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biosensors are taken at a cortical micron depth  for about 20-30 min 
time period.
NMI studies in PD and non-PD animal model
A classical animal model of PD was used to study endogenous brain 
mechanisms of PD in Sprague-Dawley rat (Rattus norvegicus). Depletion 
of DA was produced by injecting the neurotoxin, 6-hydoxydopamine 
(6-OHDA) into substantia nigra (SN) of male, Sprague-Dawley Rattus 
norvegicus in Charles River Laboratories, North Carolina, USA. 
This leads to the death of lesioned DA neurons and subsequently to 
disruption in dorsal striatum (DStr) and hence depletion of DA in 
DStr. The lesion was made in the substantia nigra (SN) of rats under 
anesthesia. Stereotaxic coordinates were AP=-1.5, ML=+1.8, DV=7.5 
[19]. 
Another group of animals, same weight (approx. 300 grams) and 
age, did not undergo surgery for lesions in SN. These were the controls 
or non lesioned groups (Non-PD). 
For NMI studies, BRODERICK PROBE® biosensors were 
implanted in both PD (lesioned) and non-PD (non-lesioned) animals 
in DStr under sodium pentobarbital anesthesia (50 mg/kg ip) [20]. 
Protocols for NMI studies with PD and non-PD were performed at 
Dr. Broderick’s laboratory with approval from the Institutional Animal 
Care and Use Committee (IACUC). These studies were performed 
to compare endogenous neurochemical profiles of PD and non-PD 
animal model.
Results and Discussion
Clinical studies with epilepsy patient, in situ and in vivo 
During early neurodegeneration, monoamines are predominant 
in resected epileptogenic tissue of brain (Gray matter) as evident 
from NMI results from the BRODERICK PROBE® biosensor. Results 
showed a relatively high concentration of DA compared to 5-HT were 
present in patient’s hippocampal pyramidal layer of brain. Lauric acid is 
a saturated fatty acid with a 12-carbon atom chain. It has a hydrophobic 
head with hydrophilic tail which helps to act as a surfactant to reduce 
surface tension. This surfactant also acts to assist the migration of 
molecules to form an oriented, adsorbed film on the interfacial surface 
of the indicator sensor.
Figure 3 depicts recordings from actual human epilepsy neocortex 
during intraoperative surgery. Epileptogenic tissue recorded from 
brain shows late neurodegeneration. A predominance of L-tryptophan 
(L-TP) and neuropeptides DYN A and SRIF over monoamines are 
observed. Therefore, results show that L-TP and neuropeptides (DYN 
A and SRIF) may be biomarkers for neurodegeneration. 
Intraoperative images were verified by comparison with a fourteen 
year empirical database on epilepsy. Table 1 represents preliminary 
data of detection limits for different compounds that were studied 
intraoperatively using the NMI biotechnology. 
Preclinical studies in animal models (PD v/s. non-PD, in situ, 
in vivo)
Figure 4 depicts an abundant presence of neurotransmitter 
peptides, neuropeptides and a lower concentration of the indoleamine, 
5-HT, while DA, expectedly, was not imaged in any PD animal model. 
Meanwhile, the non-lesioned group in figure 5 exhibited significant 
concentrations of monoamines, DA and 5-HT while neuropeptides 
were not observed in any non-PD animal model. 
Conclusion
Results showed that the precursor to 5-HT, which is L-TP, 
and the neuropeptides DYN A and SRIF may be biomarkers for 
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Figure 3: In vivo, NMI results from actual epilepsy patient studied 
intraoperatively showing late neurodegeneration. On the x-axis: oxidation 
potential (E/V) in millivolts (mV). On the y-axis: current (i/A) in microamperes. 
Minimal concentrations of dopamine (DA), homovanillic acid (HVA), serotonin 
(5-HT), and high concentrations of L-tryptophan (L-TP) (precursor to 5-HT), 
and neuropeptides (dynorphin and somatostatin) are present. 
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Figure 4: NMI results from lesioned group (PD animal model) with endogenous 
neurochemical profile. On the x-axis: oxidation potential in term of applied 
voltage in volts (V). On the y-axis: current in nanoamperes (nA). NMI was 
conducted using the BRODERICK PROBE® laurate biosensor. Serotonin (5-
HT), L-tryptophan (L-Trp) and neuropeptides (dynorphin and somatostatin) 
were present. Note that dopamine (DA) neurotransmitter was absent in 
lesioned group (PD).
Detection 
Limits-In vitro
Detection 
Limits-In vivo
Approximate 
Neurochemical 
Concentration
Catecholamine DA 2 nM 20 nM ~0.2 nM
Serotonin 5-HT 1 nM 10 nM ~0.5 nM
Homovanillic Acid HVA 20 nM 0.2 µM 7 nM
Tryptophan L-TP 20 nM 0.2 µM 1 µM
Dynorphin DYN 4 nM 40 nM 2 µM
Somatostatin SRIF 3.7 nM 37 nM 4 µM
Table 1: Preliminary data: detection limits for compounds studied intraoperatively.
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neurodegeneration. The appearance of L-TP and neuropeptides in 
late neurodegeneration of epilepsy patients and in the lesioned group 
(PD animal model) support our proposal that neuropeptides appear as 
biomarkers of neurodegeneration. We are the first to propose peptide 
appearance as biomarker molecule following neurodegeneration in 
epilepsy patients and Parkinson’s disease. Furthermore, since DYN A 
is comprised of glutamate and SRIF has been shown to alleviate the 
symptoms of PD in animal models [20,21], we simply suggest that 
DYN A may be the excitatory molecule in neurodegeneration whereas 
SRIF may provide neuroprotection in PD. Our findings provide new 
avenues for effective diagnoses and detection by using these common 
biomarkers against neurodegenerative disorders.
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laurate biosensor. Dopamine (DA), serotonin (5-HT) and L-tryptophan (L-Trp) 
were present in high concentration with minimal homovanillic acid (HVA). 
Neuropeptides were completely absent in non lesioned group (non-PD).
